Know Cancer

forgot password

Study of Pemetrexed Disodium Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous Cell Lung Cancer: a Phase IIA Pharmacogenomic Trial

Phase 2
18 Years
Open (Enrolling)
Carcinoma, Non Small Cell Lung

Thank you

Trial Information

Study of Pemetrexed Disodium Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous Cell Lung Cancer: a Phase IIA Pharmacogenomic Trial

This is a non-randomized, phase IIA pharmacogenomic, open label, uncontrolled, efficacy
study in patients with advanced non-squamous cell lung cancer as a first line therapy.

Inclusion Criteria:

- Histologic or cytologic diagnosis of non-squamous NSCLC, that is not amenable to
curative treatment with surgery or radiation therapy. This population encompasses
advanced stage patients with select stage IIIB (with pleural or pericardial effusion)
or stage IV disease. Histologic or cytologic documentation of recurrence is required
in patients who were previously completely resected and now have progressive disease.

- Tissue must be available to generate and apply the genomics predictor. If not
obtained at the time of diagnosis, then subject must consent to another biopsy. If
patient had prior radiation therapy, tissue biopsy for genomics analysis must be
outside radiation field.

- At least one, non-radiated, measurable lesion by RECIST criteria.

- ECOG performance status of 0 or 1

- No prior chemotherapy, biologic or targeted therapy for any malignancy.

- Prior radiation therapy is permitted if ≥1 week since completion of radiation
treatment. Radiation must be <25% of bone marrow reserve.

- Age greater than 18 years.

- No previous or concomitant malignancy in the past 5 years other than surgical
management for carcinoma in situ of the cervix or basal cell or squamous cell
carcinoma of the skin.

- No other serious medical or psychiatric illness.

- Signed informed consent.

- Females of child-bearing potential (not surgically sterilized and between menarche
and 1 year post menopause) must test negative for pregnancy within 7 days prior to or
at the time of enrollment based on a serum pregnancy test. Both sexually active males
and females of reproductive potential must agree to use a reliable method of birth
control, as determined by the patient and their health care team, during the study
and for 3 months following the last dose of study drug.

- Required laboratory data within two weeks of enrollment:

1. ANC or AGC greater than 1500 per uL

2. Platelets greater than 100,000 per uL

3. Total bilirubin less than 1.5mg/dL

4. Creatinine clearance greater than or equal to 45 ml/min.

5. SGOT/SGPT less than or equal to 3x/ULN except in presence of known hepatic
metastases in which it may be up to 5x ULN.

Exclusion Criteria:

- Patients with squamous cell NSCLC.

- Treatment within the last 30 days with a drug that has not received regulatory
approval for any indication at the time of study entry.

- Concurrent administration of any other anti-tumor therapy.

- Inability to comply with protocol or study procedures.

- Active infection requiring IV antibiotics, antifungal or antiviral agents, that in
the opinion of the investigator would compromise the patient's ability to tolerate

- Documented symptomatic or untreated central nervous system (CNS) metastases (except
if adequately treated and stable for at least 2 weeks).

- Major surgery within 2 weeks of study or other serious concomitant systemic disorders
that, in the opinion or the investigator, would compromise the safety of the patient
or compromise the patient's ability to complete the study.

- Myocardial infarction having occurred less than 6 months before inclusion, any known
uncontrolled arrhythmia, symptomatic angina pectoris, active ischemia or cardiac
failure not controlled by medications.

- Have peripheral neuropathy of CTCAE Grade 1 or higher

- Contraindications to corticosteroids.

- Inability or unwillingness to take folic acid or vitamin B12 supplementation.

- Unwillingness to stop taking herbal supplements while on study.

- Presence of clinically significant third-space fluid collections (for example,
ascites or pleural effusions) that cannot be controlled by drainage or other
procedures prior to study entry and throughout study enrollment as the distribution
of pemetrexed in this fluid space is not fully understood.

- Recent (within 30 days before enrollment) or concurrent yellow fever vaccination.

- Have prior known allergic/hypersensitivity reaction to any of the components of study

- Inability to discontinue administration of aspirin at a dose greater than 1300 mg/day
or other non-steroidal anti-inflammatory agents for 2 days before, the day of, and 2
days after the dose of pemetrexed (5 days for long-acting agents such as piroxicam).

- Female patients that is pregnant or breast-feeding.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective response rate

Outcome Time Frame:

Time to progression

Safety Issue:


Principal Investigator

José Miguel Sánchez Torres, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Spanish Lung Cancer Group


Spain: Spanish Agency of Medicines

Study ID:




Start Date:

January 2010

Completion Date:

December 2013

Related Keywords:

  • Carcinoma, Non Small Cell Lung
  • Phalcis
  • BRCA1
  • RAP80
  • TS
  • First line
  • Non-squamous
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung